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Abstract
Background: Positron-emission tomography and the radioligand [
11C](R)-PK11195 have been used for the imaging
of the translocator protein (TSPO) and applied to map microglia cells in the brain in neuropsychiatric disorders.
[
11C](R)-PK11195 binding has been quantified using reference region approaches, with the reference defined
anatomically or using unsupervised or supervised clustering algorithms. Kinetic compartment modelling so far has
not been presented. In the present test-retest study, we examine the characteristics of [
11C](R)-PK11195 binding in
detail, using the classical compartment analysis with a metabolite-corrected arterial input function.
Methods: [
11C](R)-PK11195 binding was examined in six control subjects at two separate occasions, 6 weeks apart.
Results of one-tissue and two-tissue compartment models (1TCM, 2TCM) were compared using the Akaike criteria
and F-statistics. The reproducibility of binding potential (BPND) estimates was evaluated by difference in
measurements (error in percent) and intraclass correlation coefficients (ICCs).
Results: [
11C](R)-PK11195 binding could be described by 2TCM which was the preferred model. Measurement error
(in percent) indicated good reproducibility in large brain regions (mean error: whole brain 4%, grey matter 5%), but
not in smaller subcortical regions (putamen 25%, caudate 55%). The ICC values were moderate to low, highest for
the white matter (0.73), whole brain and thalamus (0.57), and cortical grey matter (0.47). Sizeable [
11C](R)-PK11195
BPND could be identified throughout the human brain (range 1.11 to 2.21).
Conclusions: High intra-subject variability of [
11C](R)-PK11195 binding limits longitudinal monitoring of TSPO
changes. The interpretation of [
11C](R)-PK11195 binding by 2TCM suggests that the presence of specific binding to
TSPO cannot be excluded at physiological conditions.
Keywords: translocator protein, [
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Background
The translocator protein (TSPO), formerly known as the
peripheral benzodiazepine receptor (PBR), is widely
expressed in peripheral organs, in white blood cells and
in the brain parenchyma, predominantly in glial cells
[1,2]. The subcellular localisation of TSPO is primarily
at the outer mitochondrial membrane, where the TSPO
is part of a multimeric protein complex including the
voltage-dependent anion channel protein required for
benzodiazepine binding and an adenine nucleotide car-
rier of yet unknown function [3]. A functional role of
TSPO and the entire multimeric protein complex has
been implicated in a range of cellular biochemical path-
ways, such as cholesterol transport and steroidogenesis,
membrane biogenesis, immunomodulation and oxidative
processes [3].
The first radioligand developed for examination of
TSPO binding in vitro was [
3 H]PK11195 [1-(2-chloro-
phenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline
carboxamide] [4]. [
3 H]PK11195 is a highly selective
antagonist at the TSPO with a nanomolar affinity in rat
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nM) in vitro [5]. The radioligand [
3 H]PK11195 has been
used to examine TSPO density in the brain and showed
increased binding in brain injury as well as neurodegen-
erative and neuroinflammatory disorders [6,7].
Subsequent molecular imaging studies using
11C-
labelled PK11195 have been in line with postmortem
findings, i.e. increased TSPO binding has been observed
in patients with multiple sclerosis, Alzheimer’sd i s e a s e ,
Parkinson’s disease, epilepsy, encephalitis and other cen-
tral nervous system (CNS) disorders (see review [8]).
Despite a low signal-to-background ratio, [
11C](R)-
PK11195 binding to TSPO has been suggested as a
potential biomarker of neuroinflammatory and neurode-
generative processes. A common assumption in studies
with [
11C](R)-PK11195 is that the radioligand has no
specific binding in the brain in vivo at physiological con-
ditions. However, even with the wide applications of
[
11C](R)-PK11195, a full kinetic compartment analysis
has not been published, and the reproducibility of [
11C]
(R)-PK11195 binding is limited to linear graphical, spec-
tral cluster analysis and reference region-based methods
[9].
The purpose of the present study was to examine [
11C]
(R)-PK11195 binding using a full kinetic compartment
analysis with a metabolite-corrected arterial input func-
tion. Six control subjects were examined twice, on separate
days, so as to extend test-retest examination for compart-
ment analysis.
Methods
The study was approved by the Regional Ethics Commit-
tee in Stockholm and the Radiation Protection Committee
at the Karolinska University Hospital, Stockholm. Written
informed consent was obtained from each subject.
Subjects
The study group consisted of six subjects, all men, mean
age 25.8 ± 3.9 years (range 21 to 31 years). Participants
were recruited at the AstraZeneca Clinical Pharmacology
Unit, Karolinska University Hospital, Huddinge, Stock-
holm. They were healthy according to the medical history,
clinical examination, and routine laboratory blood and
urine tests. No medications were used at the time of the
study. No anatomical brain abnormality was detected on
magnetic resonance imaging (MRI) in any subject as eval-
uated by a neuroradiologist at the Karolinska University
Hospital.
The molecular imaging examinations were carried out at
the PET Centre, Department of Clinical Neuroscience,
Karolinska Institutet, Stockholm. All subjects underwent
two positron-emission tomography (PET) measurements
approximately 6 weeks apart.
Radiochemistry
[
11C](R)-PK11195 was prepared by N-methylation of the
desmethyl precursor at room temperature, with slight
modifications of a synthesis [10]. In short, [
11C]methane
was produced in-target via the
14 N(p,a)
11C reaction on
aN 2-H2 gaseous system, in a GEMS PET trace cyclo-
tron. [
11C]methyl iodide was produced according to pre-
viously published methods [11]. [
11C]CH3I was trapped
in a solution of a precursor (0.5 mg) and potassium
hydroxide (5 mg) in dimethylsulfoxide (300 μL). After
the synthesis of [
11C](R)-PK11195, the radioligand was
dissolved in a sterile disodium phosphate-buffered saline
solution, pH 7.4, and filtered through a sterile Millex-
GV filter (0.22 μm; Millipore AB, Solna, Sweden).
The mean decay-corrected radiochemical yield (n = 12)
of [
11C](R)-PK11195 was 9.1%, and the radiochemical
purity of the final product was > 98%. The specific radio-
activity of the radioligand injected varied between 421
and 2,303 GBq/μmol (11,390 and 62,249 Ci/mmol), cor-
responding to an injected total mass of 0.05 to 0.23 μg.
The radioactivity injected was 302 ± 33 MBq (mean ±
standard deviation (SD); 12 measurements).
MR imaging
The three-dimensional (3D) MR protocol comprised Sie-
mens 3D T1-weighted magnetization-prepared rapid
acquisition with gradient echo (MPRAGE) sequences.
Images were obtained with a Siemens 1.5 T Magnetom
with an eight-channel parallel coil, using a GRAPPA-accel-
erated protocol with 3D sequences covering the whole
brain with isotropic voxel sizes (1.3 × 1.3 × 1.3 mm) [12].
PET measurement procedure
Each subject was placed recumbent with the head in the
PET system. A head fixation system with an individual
plaster helmet was used. A cannula was inserted into the
left radial artery and another into the right antecubital
vein. A sterile phosphate buffer (pH = 7.4) containing radi-
oligand was injected as a bolus over 2 s into the cubital
vein. The cannula was then immediately flushed with a
10-mL saline solution. In each individual, the measure-
ment was repeated after approximately 6 weeks.
The PET system used was ECAT Exact HR 47 (Siemens/
CTI, Knoxville, TN, USA), with an in-plane and an axial
resolution of 3.6 and 4.0 mm, respectively, full width at
half maximum (FWHM). The radioactivity in the brain
was measured continuously for 60 min using a pre-pro-
grammed sequence of 29 frames (20 s × 9, 30 s × 6, 180 s
× 5, 300 s × 5). The system was run in 3D mode, and the
reconstructed volume was displayed as 47 sections with a
centre-to centre distance of 3.125 mm. The images were
reconstructed with a Hanning filter (FWHM = 2 mm) in a
matrix of 128 × 128 × 47 voxels, yielding a voxel size of
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using transmission scan data obtained for each subject.
Arterial blood sampling
To obtain the arterial input function, an automated blood
sampling system was used during the first 5 min of each
PET measurement. Thereafter, arterial blood samples
(2 mL) were drawn manually at the midpoint of each
frame until the end of measurement [13]. The radioactivity
in 1 mL of the manually drawn samples was then immedi-
ately measured for 10 s in a well counter cross-calibrated
with the PET system. After centrifugation, 0.2 mL plasma
was pipetted and plasma radioactivity was measured in a
well counter.
Plasma metabolite analysis of [
11C](R)-PK11195 using
HPLC
The method for the determination of the fraction of radio-
activity corresponding to unchanged [
11C](R)-PK11195
and labelled metabolites during the time of a PET mea-
surement was a modification of a high-performance liquid
chromatography (HPLC) method developed for other PET
radioligands [14]. Arterial blood samples (2 mL) were
obtained at 4, 10, 20, 30, 40 and 50 min after injection of
[
11C](R)-PK11195. After centrifugation at 2,000 × g for
2 min, plasma was obtained (0.5 mL) and mixed with acet-
onitrile (0.7 mL). The mixture was centrifuged at 2,000 × g
for 2 min, and the supernatant (1 mL) was injected to a
HPLC system. The blood (2 mL) and plasma (0.5 mL)
were counted in a NaI well counter. The HPLC system
used consisted of a Merck-Hitachi D-7000 interface mod-
ule, a Merck-Hitachi L-7100 pump and a Rheodyne injec-
tor (7125 with a 5.0-mL loop) (VWR International,
Stockholm, Sweden) equipped with a Waters/-Bondapack-
C18 column (300 mm × 7.8 mm, 10-μm particle size;
Waters, Milford, MA, USA) and a Merck-Hitachi L-7400
absorbance detector (254 nm) in series with a Packard
Radiomatic 150TR radiometric detector (Packard
BioScience, Meriden, CT, USA) equipped with a PET flow
cell (600-μL cell). The HPLC methods used were acetoni-
trile (A) and phosphoric acid (0.01 M) (B) as mobile phase
at 6.0 mL/min. The program was as follows: 0 to 5 min
(A/B) 35/65 to 80/20, 5 to 7.5 min (A/B) 80/20 to 35/65
and 7.5 to 10 min (A/B) 35/65. The radioactive peak hav-
ing a retention time corresponding to [
11C](R)-PK11195
was integrated, and its area was expressed as a percentage
of the sum of the areas of all detected radioactive peaks.
Image analysis
MR image pre-processing
The T1-weighted MPRAGE images were co-registered to
a template atlas, inhomogeneitycorrected, masked and
segmented through a fuzzy c-means cluster algorithm
into grey matter, white matter and cerebrospinal fluid
membership images using the in-house software BMAP/
Volstat [12].
The original MR images and segmented grey and
white matter images were re-oriented and re-aligned to
the anterior-posterior commissural plane, re-sampled
and cropped to generate a 256 × 256 × 144 matrix with
1-mm
3 voxels.
PET image pre-processing
The 4D PET images were integrated over time to obtain
3D PET summation images. The PET images were co-
registered to the re-oriented, high-resolution T1-weighted
MRI. The summation PET images were used to determine
the co-registration parameters (rotation and translation
required). The co-registered PET images were re-sliced to
a voxel size of 2 × 2 × 2 mm. The spatial processing of
MR and PET images was performed in SPM5 (Wellcome
Department of Cognitive Neurology, UK).
Regions of interest
Regions of interest (ROIs) were processed in two different
ways. Anatomically defined ROIs (caudate nucleus, puta-
men, thalamus and brainstem) were manually delineated
on the reoriented T1-weighted MR image using an in-
house image analysis software, Human Brain Atlas. Three
additional brain tissue ROIs (whole brain, all grey matter
and all white matter) were obtained automatically.
A whole brain region was created taking the union of all
white and grey matter. The additional ‘grey matter’ and
‘white matter’ ROIs were derived by the following steps:
(1) MR image segmentation into the white and grey mat-
ter, (2) creation of a thalamus-brainstem mask using ana-
tomical ROIs, (3) subtraction of the mask in (2) from the
segmented regions in (1). These regions represent the grey
matter and the white matter without the brainstem-
thalamus regions, respectively. The grey matter region was
coregistered to summation PET image voxels. The most
common radioactivity values were used to create a brain
region representing a ‘typical grey matter (GM)’ ROI.
Radioligand brain exposure
To calculate the percentage of [
11C](R)-PK11195 injected
that was present in the brain at the time of maximal radio-
activity, the radioactivity concentration in the ROI for the
whole brain was multiplied by the estimated average brain
volume (1,250 mL), divided by the radioactivity injected
and multiplied by 100 to obtain the percentage of injected
radioactivity.
Regional brain radioactivity
Average radioactivity for the ROI was calculated by pool-
ing the data from the series of brain sections. The radioac-
tivity concentration for each sequential time frame was
corrected for the physical decay of carbon-11 and used to
obtain the regional time-radioactivity curves (TACs; in
kiloBecquerels per cubic centimetre).
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Arterial blood data from the manual samplings were
interpolated to obtain curves with one data point per
second up to the end of PET acquisition. The interpola-
tion was performed using a weighted curve fit with a
smoothing factor of 0%. Blood time-activity curves were
generated by connecting the initial automated blood
sampling system curve with the interpolated curve from
later manual blood samples. Plasma and blood radioac-
tivity concentrations from manual blood samplings were
divided to obtain a plasma/blood ratio curve. The ratio
curve was inter- and extrapolated from 0 s up to the
end of acquisition by a linear fit. The extended ABSS
curve was multiplied with the fitted plasma/blood ratio
curve to obtain the plasma curve. Correction for disper-
sion as well as correction for radioligand metabolism
was performed as has been described previously [13].
Individual parent fraction data were fitted using the Hill
model [15]. Metabolite correction was performed by
multiplying uncorrected plasma curves with parent frac-
tion model curves.
Quantifications of [
11C](R)-PK11195 binding
[
11C](R)-PK11195 binding to TSPO was quantified using
kinetic compartment analyses with the metabolite-cor-
rected arterial plasma curve as input function. Two
compartment models (one- and two-tissue) were used
to fit the model to the TACs. The fractional volume of
blood present in the tissue volume and bolus time were
estimated for each individual, each occasion, by fitting
the whole brain TAC with a two-tissue compartment
model.
The one-tissue compartment model
The one-tissue compartment model (1TCM) describes
one compartment which is a composite of free, non-
specifically and specifically bound radioligands [16]. The
two rate constants, K1 and k2, describe the influx and
efflux rates across the blood-brain barrier, respectively
[17].
The two-tissue compartment model
The two-tissue compartment model (2TCM) has been
described in detail in the literature [13,18,19]. The two-
tissue compartments are defined as the radioactivity con-
centration of a nondisplaceable radioligand in the brain
(CND) and the radioactivity concentration of a radioli-
gand specifically bound to receptors (CB). In this model,
four rate constants (K1, k2, k3 and k4) explain the time
curves for radioligand in the brain. In short, the four rate
constants were determined by curve fitting with a
weighted non-linear least squares fitting technique with
constraint-restricting parameters between 0 and 0.9.
Each initial value for K1, k2, k3 and k4 was 0.5, 0.1, 0.5
and 0.5, respectively. The local minimum of the sum of
the squared residuals was determined by iteration.
Regional [
11C](R)-PK11195 binding was expressed
using the concept of the total distribution volume (VT),
which is defined by the following equation, using kinetic
constants obtained from 2TCM [16,20,21].
VT = K1/k2(1 + k3/k4)
The [
11C](R)-PK11195 distribution volume was also
quantified using a linear graphical analysis for reversible
ligand binding [22]. The regional distribution volumes
were determined from the slope of the linear plots
obtained from 8 to 60 min after intravenous (i.v.) injec-
tion using the radioactivity of unchanged [
11C](R)-
PK11195 in arterial plasma as an input function.
Specific [
11C](R)-PK11195 binding was expressed as
binding potential relative to nondisplaceable binding
(BPND) as follows:
BPND = fNDBmax/Kd = k3/k4
where Bmax is the receptor density, Kd is the affinity,
and fND is the free fraction of ligand in the nondisplace-
able tissue compartment [19]. However, protein binding
of [
11C](R)-PK11195 in plasma was not measured in the
study, and fND was not included in the calculations.
The fractional volume of blood present in the tissue
volume was determined for each individual, each occa-
sion. It was obtained by fitting whole brain TAC with a
2TCM with six parameters (K1, k2, k3, k4, fractional
blood volume (VB) and time shift between plasma input
function and PET TAC (tbolus)) and parameters VB and
tbolus subsequently applied for each brain region.
The two-tissue compartment model, modified
I na d d i t i o n ,d a t aw e r ea n a l y s e du s i n gam o d i f i e d2 T C M
model which fitted parameters K1/k2, k2, k3 and k4 of the
model to several TACs simultaneously in a way that the
parameter K1/k2 was shared between regions. First, all
ROIs primarily consisting of the grey matter, including
the ROI of the typical GM uptake, were fitted in this way
then followed by a fit involving white matter regions and,
again, the ROI of the typical GM uptake. The ROI of the
typical GM uptake was used in the second fitting session
to allow for a coupling of K1/k2 b e t w e e nt h a tr e g i o na n d
white matter ROIs. However, the parameters obtained
for the the typical GM ROI in the first session were
retained for final analysis.
Statistics
The Akaike information criterion [23] and F-statistics
[13] were used to determine which compartment model
provided the best fit to the data. F-statistics was one-
tailed (right).
The reproducibility of two successive PET measure-
ments was analysed by means of descriptive statistics
(mean, range, SD, coefficient of variance (CV), difference
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lation coefficient (ICC)). The ICC was calculated from
the between-subject and within-subject variations, using
the expression:
ICC = (MSBS − MSWS)/[MSBS +( n − 1)MSWS]
where MSBS denotes the between-subject mean
square; MSWS, the within-subject mean square; and n,
the number of repeated observations (i.e. 2).
The descriptive statistics and computations for test-ret-
est analysis were performed using the STATISTICA sys-
tem, version 10.0 (StatSoft, Inc., Tulsa, OK, USA). In all
analyses, the statistical significance (alpha level) was set at
p <0 . 0 5 .
Results
After intravenous injection of [
11C](R)-PK11195, the
TACs for total brain radioactivity reached a peak at
approximately 1 min after injection. At this time, about
2.5% (range from 1.9% to 3.2%, n = 6) of radioactivity
injected (ID%) was present in the brain, and mean ID%
decreased to about 1.5% to 1.3% during the measurement
time from 20 to 60 min. The radioactivity ratio of whole
brain to plasma (corrected for metabolites) increased with
time and ranged between 0.5 and 2 (n = 6) by the end of
the PET measurement (Figure 1).
HPLC analysis of [
11C](R)-PK11195 metabolites in
plasma identified the parent compound and radioactive
metabolites (Figure 2A, sample at 20 min after injection).
The metabolites were more polar than the parent com-
pound. The unchanged fraction of [
11C](R)-PK11195 was
70 ± 1.5% (range 60% to 77%) by the end of PET measure-
ment time (Figure 2B). For all brain regions, the 1TCM
and the 2TCM were fitted to experimental data using the
metabolite-corrected arterial plasma curve as input func-
tion (Figure 3A, B).
The single rate constants obtained by the 1TCM and
2TCM during repeated PET measurements are given in
Tables 1 and 2. The ratio of K1 to k2 was obtained by the
2TCM. The comparison of models showed that the
2TCM was statistically preferred to describe the time-
activity curves of [
11C](R)-PK11195 in all brain regions
and in all subjects. The fractional cerebral blood volume
across all occasions ranged from 4.4% to 7% (6 ± 0.009%,
mean ± SD). In addition, the fitting procedure was carried
out with the modified 2TCM-2 using a shared K1/k2.
Kinetic constant values were similar to the ones obtained
by classical 2TCM, and there was no significant improve-
ment in statistics compared to 2TCM data (Akaike cri-
teria) (see Table 3 and Tables 1 and 2 for comparison).
Numerical values for specific binding (BPND = k3/k4)
throughout the brain regions varied twofold (Table 4,
Figure 4).
Test-retest analysis
The test-retest variability for BPND (k3/k4)v a r i e d
between brain regions. The mean difference between
two PET measurements was lowest in the cortical grey
matter (5%), white matter (-4%), cerebellum and white
matter (-8%) regions and highest in the dorsal striatum
and thalamus (-55% and -29%, respectively) (Table 4,
individual data in Figure 5). The ICC values for [
11C]
(R)-PK11195 were fair to moderate in the thalamus,
grey matter, white matter and whole brain regions, but
were of low reproducibility in the striatum, brainstem
and cerebellum.
The VT analysis has been widely used for quantifica-
tion of [
11C](R)-PK11195 binding. Test-retest analysis of
VT showed lower error compared to the BPND (k3/k4)
data, though VT values (for 2TCM) also tended to be
higher in the striatum than in the cortex or whole brain
(Table 5).
Discussion
Several CNS disorders are accompanied by the activation
of microglia which is thought to be a part of the disease
pathophysiology. In an era of emerging new therapies aim-
ing to modify disease progression, it is critical to have a
biomarker that enables the monitoring of disease course
and effects of therapeutic interventions at the cellular
level. Molecular imaging using radioligand binding to mar-
kers of microglia has potential to serve this purpose. Ide-
ally, the imaging signal has to be highly reproducible,
sensitive to changes, and the underlying biology has to be
well understood. All these features have been in focus in
the development of the reference radioligand [
11C](R)-
PK11195 and a subsequent series of radioligands binding
to the TSPO.
In the present study, a detailed analysis of [
11C](R)-
PK11195 binding using arterial input function and full
kinetic compartment modelling was performed. The two-
tissue compartment model was the statistically preferred
model, and the BPND values were of the same order as
seen for commonly used radioligands binding to receptors
or transporters. The study results were in line with the
BPND values presented in by the initial kinetic compart-
ment analysis [24] and clinical studies [25].
The present study included a preliminary analysis of
reliability of the quantitative analysis for [
11C](R)-PK11195
binding potential, BPND (k3/k4), using a test-retest
approach. The mean difference between test and retest
was lowest in large regions such as the whole brain, corti-
c a lg r e ym a t t e ra n dw h i t em atter, and was high in the
smaller brain regions. These reproducibility values are
acceptable for studies where analysis of [
11C](R)-PK11195
binding is limited to larger brain regions, however, is
insufficient for quantitative analysis in small regions. In
addition, the twofold inter-individual variability in [
11C]
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indicates that studies with group comparisons may require
large sample size. Another important factor that may con-
tribute to the variability of radioligand binding to TSPO is
the presence of several binding sites with different affi-
nities dependent on single nucleotide polymorphism of
TSPO, at Ala147Thr [26]. However, high inter-individual
variability in [
11C](R)-PK11195 binding cannot be
explained by TSPO SNP variants, as it has been demon-
s t r a t e dt h a tt h i si st h eo n l yr a d i o l i g a n dn o ts e n s i t i v et o
TSPO genotype [27].
The [
11C](R)-PK11195 binding was homogenously dis-
tributed in the human brain (Tables 1 and 2, Figure 4,
[28]). Following the advent of [
11C](R)-PK11195, a com-
mon assumption has been that the constitutive expres-
sion of TSPO in the brain is low or negligible [9,29].
Figure 1 R a t i oo fb r a i nc o n c e n t r a t i o no f[
11C](R)-PK11195 to plasma concentration over time. (Plasma concentration is corrected for
metabolites).
Figure 2 Metabolism of [
11C](R)-PK11195.( A) Radiochromatogram from gradient HPLC analysis of human plasma after i.v. injection of [
11C](R)-
PK11195 (peak III). Peaks I and II represent labelled metabolites that are more polar than unchanged [
11C](R)-PK11195. (B) Time course for the
fraction (%) of radioactivity in plasma that represents unchanged [
11C](R)-PK11195 and its metabolites in six healthy human subjects (mean, SD).
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analyses where higher binding in a certain brain region
is viewed as ‘microglia activation’ c o n t r a s t i n gt oab a c k -
ground of non-specific binding. More recently, compart-
ment analysis of [
11C](R)-PK11195 binding applied in
clinical studies has consistently demonstrated a binding
compartment also in control subjects [30,31]. However,
the nature of this compartment has not been discussed
in detail.
In early studies using [
3 H]-labelled PK11195, the
TSPO density (Bmax) in autopsies of normal human brain
has been quantified in detail by autoradiography [1]. The
TSPO binding sites were shown to be widespread and
with high density in several subcortical nuclei, with more
moderate binding in the cortex and dorsal striatum. Sub-
sequent studies have consistently confirmed the initial
findings, i.e. TSPO density in the grey matter in the
range of 684 to 923 fmol/mg protein [8,28,32]. Assuming
a 10% protein content in the brain, the corresponding
TSPO concentration in intact neural tissue should be
60 to 90 pmol/g. This TSPO concentration is of the same
order as for several neuroreceptors, e.g. the dopamine
D2/3 receptor density in the striatum (Bmax 15 pmol/g,
[26]) or the 5HT1A receptors in the neocortex (up to
120 pmol/g, [33]). For these G-protein-coupled receptors,
it has been possible to develop suitable radioligands for
molecular imaging. Thus, the TSPO density in the
human brain demonstrated in vitro conditions should be
large enough for quantitative imaging with radioligands
having sufficient affinity to TSPO. The affinity of [
11C](R)
PK11195 for TSPO is indeed in the nanomolar range
which is comparable to successful neuroreceptor ligands
such as [
11C]raclopride or [
11C]WAY 100635 (approxi-
mately 1 to 3 nM, [13,34]).
The assumption that non-specific [
11C](R)-PK11195
binding constitutes a major proportion of the signal was
based on early in vivo studies in baboons [35]. An indirect
quantitative approach was used, subtracting TSPO binding
from baseline data and suggesting that the fraction of non-
specifically bound [
11C](R)-PK11195 in the grey matter is
about 60%. For new radioligands such as [
11C]DAA1106,
specific binding constitutes 80% to 90% of the total bind-
ing in the monkey brain [36]. Interestingly, unlabelled
PK11195 has been shown to displace about 70% of the
total [
11C]DAA1106 binding [36], and PBR28 could dis-
place [
11C](R)-PK11195 binding up to 40% to 60% [37],
thus, providing indirect support for the presence of size-
able specific TSPO binding.
Quantitative analysis of radioligand binding may be
influenced by a number of conditions, including formation
of radioactive metabolites that may enter the brain. The
present study confirms that the metabolism of [
11C](R)-
PK11195 is not extensive [38] and metabolites less polar
than the parent compound could not be identified. Thus,
there is no support for the interpretation that a metabolite
could cross the BBB and represent the compartment for
specific binding identified by the 2TCM.
The 2TCM analysis provided values for individual rate
constants, which were in line with the initial results of
the kinetic compartment modelling of [
11C](R)-PK11195
[24]. The influx rate constant K1 (0.05 to 0.09) was low
when compared to K1 values obtained for other radioli-
gands in the same experimental setting and using the
same analytical approach (e.g. 0.16 for [
11C]raclopride,
Figure 3 Experimental values for regional radioactivity in the grey and white matter in one subject. The corresponding fitted curves are
obtained by the 1TCM (A) and by the 2TCM (B).
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Page 7 of 13Table 1 Comparison of kinetic constants in 1TCM and 2TCM for [
11C](R)-PK11195 binding in the grey matter
Subject Test (1); retest (2) Model K1 (mL/cc/min) k2 (min
-1) k3 (min
-1) k4 (min
-1) K1/k2 k3/k4 (BPND) AIC F-statistics (1TCM/2TCM; p value)
1 1 1TCM 0.074 0.116 0.64 239
2TCM 0.094 0.264 0.076 0.067 0.36 1.13 171 3 × 10
-14
2 1TCM 0.056 0.099 0.57 264
2TCM 0.073 0.234 0.059 0.044 0.31 1.33 197 4 × 10
-14
2 1 1TCM 0.054 0.096 0.55 253
2TCM 0.072 0.252 0.058 0.026 0.28 1.86 173 1 × 10
-16
2 1TCM 0.057 0.118 0.48 274
2TCM 0.077 0.287 0.059 0.041 0.27 1.44 211 2 × 10
-13
3 1 1TCM 0.062 0.086 0.72 264
2TCM 0.082 0.220 0.061 0.033 0.39 1.55 181 < 1 × 10
-323
2 1TCM 0.094 0.111 0.84 286
2TCM 0.129 0.318 0.111 0.076 0.41 1.47 210 9 × 10
-16
4 1 1TCM 0.037 0.087 0.41 236
2TCM 0.048 0.220 0.055 0.038 0.22 1.45 179 3 × 10
-12
2 1TCM 0.035 0.086 0.41 236
2TCM 0.049 0.246 0.062 0.035 0.20 1.80 178 2 × 10
-12
5 1 1TCM 0.062 0.111 0.56 283
2TCM 0.082 0.245 0.040 0.023 0.33 1.75 184 < 1 × 10
-323
2 1TCM 0.044 0.108 0.41 288
2TCM 0.067 0.340 0.068 0.032 0.20 2.08 204 < 1 × 10
-323
6 1 1TCM 0.042 0.106 0.39 267
2TCM 0.054 0.221 0.038 0.029 0.24 1.27 197 1 × 10
-4
2 1TCM 0.045 0.091 0.49 272
2TCM 0.060 0.239 0.065 0.045 0.25 1.44 231 3 × 10
-9
Mean 1 1TCM 0.055(0.014/25) 0.100(0.012/12) 0.54(0.13/23) Mean 1 1TCM
(SD/CV) 2TCM 0.072(0.018/25) 0.237(0.019/8) 0.055(0.014/25) 0.029(0.011/38) 0.30(0.06/21) 1.50(0.27/18) (SD/CV)
2 1TCM 0.055(0.021/18) 0.102(0.012/12) 0.53(0.16/31)
2TCM 0.076 (0.028/37) 0.277(0.045/16) 0.071(0.02/28) 0.046(0.016/34) 0.27(0.08/29) 1.59(0.29/18)
Data from the first PET measurement used for all subjects. 1TCM, one-tissue compartment model; 2TCM, two-tissue compartment model; SD, standard deviation; CV, coefficient of variation; AIC, Akaike information
criteria
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3Table 2 Comparison of kinetic constants in 1TCM and 2TCM for [
11C](R)-PK11195 binding in the white matter
Subject Test (1); retest (2) Model K1 (mL/cc/min) k2 (min
-1) k3 (min
-1) k4 (min
-1) K1/k2 k3/k4 (BPND) AIC F-statistics (1TCM/2TCM; p value)
1 1 1TCM 0.055 0.086 0.64 228
2TCM 0.067 0.165 0.037 0.030 0.41 1.21 180 2 × 10
-10
2 1TCM 0.042 0.071 0.59 250
2TCM 0.051 0.144 0.033 0.022 0.35 1.49 198 3 × 10
-11
2 1 1TCM 0.044 0.071 0.61 244
2TCM 0.056 0.176 0.043 0.019 0.32 2.20 177 4 × 10
-14
2 1TCM 0.046 0.089 0.52 267
2TCM 0.060 0.206 0.042 0.025 0.29 1.65 208 1 × 10
-12
3 1 1TCM 0.049 0.066 0.74 250
2TCM 0.061 0.154 0.043 0.026 0.40 1.67 177 3 × 10
-15
2 1TCM 0.075 0.085 0.88 278
2TCM 0.097 0.209 0.061 0.045 0.61 1.36 212 7 × 10
-14
4 1 1TCM 0.027 0.066 0.41 223
2TCM 0.032 0.124 0.024 0.019 0.26 2.03 192 3 × 10
-7
2 1TCM 0.027 0.066 0.41 239
2TCM 0.035 0.164 0.041 0.020 0.21 2.03 176 2 × 10
-13
5 1 1TCM 0.048 0.081 0.59 274
2TCM 0.061 0.184 0.034 0.014 0.33 2.41 201 3 × 10
-15
2 1TCM 0.032 0.078 0.41 273
2TCM 0.045 0.223 0.046 0.019 0.20 2.50 208 1 × 10
-13
6 1 1TCM 0.030 0.072 0.41 255
2TCM 0.035 0.138 0.024 0.012 0.25 1.91 213 2 × 10
-9
2 1TCM 0.033 0.064 0.52 246
2TCM 0.039 0.126 0.028 0.018 0.31 1.62 175 8 × 10
-15
Mean 1 1TCM 0.042(0.011/26) 0.074(0.008/11) 0.57(0.13/23)
(SD/CV) 2TCM 0.052(0.015/29) 0.157(0.02/13) 0.034(0.009/26) 0.020(0.007/35) 0.33(0.07/20) 1.93(0.48/22)
2 1TCM 0.043(0.017/39) 0.076(0.010/13) 0.56(0.18/32)
2TCM 0.055(0.023/42) 0.179(0.040/22) 0.042(0.011/26) 0.025(0.010/40) 0.31(0.10/32) 1.78(0.42/24)
Data from the first PET measurement used for all subjects. 1TCM, one-tissue compartment model; 2TCM, two-tissue compartment model; SD, standard deviation; CV, coefficient of variation; AIC, Akaike information
criteria
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3[39]; 0.42 for [
11C]FLB-457, [40]). The lipophilicity of
[
11C](R)PK11195 (log P = 1.4 to 3.4, [38,41]) is in the
range commonly perceived as ideal for a suitable PET
ligand (1 to 3). Thus, the slow influx has to be explained
by other conditions. Theoretically, one of the reasons for
the slower influx rate and lower brain uptake of [
11C](R)-
PK11195 could be its binding to transporters at the
blood-brain barrier. However, it has been shown that
[
11C](R)-PK11195 is not a substrate for any of the three
major ABC transporters (p-glycoprotein-ABCB1 and
ABCC1, ABCG2) [37].
Most radioligands and drug molecules bind to plasma
albumin. It has been shown that drug dissociation from
albumin is very rapid [42]. Indeed, for [
11C]raclopride,
h a v i n gap l a s m ap r o t e i nb i n d i n go f9 6 % ,t h ef i r s tp a s s
extraction is about 20%, indicating sizeable dissociation
during the short capillary transit time [13]. Interestingly,
it has been shown that [
3 H]PK11195 binds with high
affinity to the alfa1-acid glycoprotein (AGP) and to a les-
s e re x t e n tt oh u m a ns e r u ma l b u m i n( H S A )[ 4 3 ] .T h e
observation that K1 for [
11C](R)-PK11195 is lower than
that for other radioligands can at least partly be explained
Table 3 Kinetic constants in 2TCM with shared K1/k2 values for [
11C](R)-PK11195 binding in 6 healthy subjects
Subject K1 (mL/cc/min) k2 (min
-1) k3 (min
-1) k4 (min
-1) K1/k2 k3/k4 (BPND) AIC
Cortical grey matter
1 0.092 0.236 0.055 0.054 0.39 1.02 170
2 0.070 0.228 0.046 0.025 0.31 1.82 173
3 0.089 0.307 0.124 0.061 0.29 2.01 195
4 0.046 0.185 0.035 0.026 0.25 1.36 180
5 0.080 0.235 0.036 0.020 0.34 1.80 183
6 0.050 0.180 0.021 0.014 0.28 1.47 204
Mean 0.071 0.228 0.053 0.033 0.31 1.58
(SD/CV) (0.019/27) (0.046/20) (0.037/69) (0.019/57) (0.05/16) (0.36/23)
White matter
1 0.067 0.169 0.040 0.033 0.40 1.02 178
2 0.056 0.180 0.045 0.021 0.31 2.18 176
3 0.062 0.159 0.046 0.027 0.39 1.68 176
4 0.032 0.129 0.026 0.013 0.25 1.97 190
5 0.061 0.182 0.033 0.013 0.33 2.46 200
6 0.036 0.138 0.024 0.012 0.26 1.97 212
Mean 0.052 0.159 0.036 0.020 0.32 1.88
(SD/CV) (0.015/29) (0.022/14) (0.009/25) (0.009/45) (0.06/19) (0.49/26)
Data from the first PET measurement only is presented for simplification purposes. SD, standard deviation; CV, coefficient of variation; AIC, Akaike information
criteria
Table 4 Test-retest characteristics of [
11C](R)-PK11195 binding to the TSPO in healthy subjects
Brain region BPND (k3/k4) Error range (%) Error % mean(SD) ICC
Test CV (%) Retest CV (%) Mean
Caudate 1.37(0.55) 40 1.92(0.87) 45 1.65 -155 to 30 -55(80) 0.01
Caudate (R) 1.33(0.68) 51 2.21(1.19) 54 1.77 -288 to12 -96(126) 0.01
Caudate (L) 1.52(0.43) 28 1.84(0.93) 51 1.68 -133 to 42 -27(66) -0.05
Putamen 1.20(0.28) 24 1.50(0.69) 46 1.38 -138 to 21 -25(63) 0.09
Putamen (R) 1.27(0.48) 37 1.56(0.73) 47 1.41 -145 to 34 -32(72) -0.01
Putamen (L) 1.28(0.31) 24 1.60(0.67) 42 1.44 -145 to 23 -30(59) 0.02
Thalamus 1.19(0.28) 23 1.53(0.45) 30 1.36 -82 to 9 -29(33) 0.57
Thalamus (R) 1.34(0.43) 32 1.86(0.56) 30 1.60 -136 to 17 -46(50) 0.16
Thalamus (L) 1.11(0.25) 23 1.42(0.59) 42 1.26 -136 to 39 -32(64) 0.17
Brainstem 2.00(0.35) 17 2.18(0.33) 15 2.09 -45 to 26 -13(31) -0.6
Cerebellum 1.29(0.19) 15 1.37(0.24) 17 1.33 -21 to 32 -8(20) 0.07
White matter 1.90(0.42) 22 1.78(0.42) 24 1.84 -25 to 21 -8(18) 0.73
Grey matter, cortex 1.50(0.27) 18 1.59(0.29) 18 1.55 -24 to 25 5(18) 0.47
Whole brain 1.65(0.33) 20 1.68(0.35) 21 1.67 -25 to 22 -4(19) 0.57
Binding potential, BPND =k 3/k4 from 2TCM; CV, coefficient of variance; ICC, intra-class correlations
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Page 10 of 13by a slower dissociation rate from AGP than from HSA.
However, a limitation of the present study was that
radioligand protein binding was not determined. If con-
firmed, this proposed interpretation may have implica-
tions for clinical studies on inflammatory disorders
known to change the rather stable levels of AGP at phy-
siological conditions [44]. In such conditions, it cannot
be excluded that K1 may show considerable inter-indivi-
dual variability.
Conclusions
The reproducibility of [
11C](R)-PK11195 binding in
large brain regions was acceptable for applied clinical
studies. However, the study showed that the use of
Figure 4 PK11195 summation images, test-retest (9- to 60-min imaging interval; normalized image intensity for injected radioactivity).
Figure 5 Binding potentials (BPND, k3/k4) obtained at repeated PET measurements in six control subjects.
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11C](R)-PK11195 as a biomarker in clinical trial is lim-
ited when detailed mapping of TSPO changes in smaller
brain regions is needed.
The [
11C](R)-PK11195 binding to TSPO could be best
described by the two-tissue compartment model. The size-
able [
11C](R)-PK11195 binding demonstrated in the pre-
sent study is consistent with the literature reporting
abundant TSPO binding sites in the human brain post-
mortem in control subjects. On the basis of these findings,
it cannot be excluded that [
11C](R)-PK11195 binding at
physiological conditions to some degree represents specific
binding to TSPO.
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